Mon. Nov 9th, 2026

WEEKLY TOP

NABEP Replaces Decades-Old Steel Lines with 1,149 Kilometers of New Pipe on Lake Maracaibo
Scientific Games Announces Annual Sustainability Report Highlighting Progress in Responsible Gaming and Environmental Stewardship
Toptal AI Launches, Delivers Frontier-grade AI With Open-weight Models and Full Data Ownership
Blockchain.com Appoints Lisa Nelson and Luis Berruga to Board of Directors

EDITOR'S CHOICE

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/r) aggressive…